Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | PDE5A | O76074 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004598 | 0.96 | KMT2A (0.88) | KMT2APDE5AALDH1A1CYP2D6GAA | |
| SCHEMBL6444862 | 0.91 | KMT2A (0.66) | KMT2APDE5AALDH1A1CYP2D6 | |
| SCHEMBL6442764 | 0.91 | KMT2A (0.66) | KMT2APDE5AALDH1A1CYP2D6GAA | |
| SCHEMBL6443105 | 0.90 | KMT2A (0.64) | KMT2APDE5AALDH1A1GAAHPGD | |
| SCHEMBL6444293 | 0.90 | KMT2A (0.65) | KMT2APDE5AALDH1A1CYP2D6GAA | |
| SCHEMBL3587341 | 0.89 | KMT2A (1.00) | KMT2APDE5AALDH1A1CYP2D6GAA | |
| SCHEMBL6441707 | 0.89 | KMT2A (1.00) | KMT2APDE5AALDH1A1CYP2D6GAA | |
| Hydrochloric Acid SCHEMBL6386723 | 0.88 | KMT2A (0.98) | KMT2APDE5AALDH1A1CYP2D6GAA | |
| SCHEMBL6441696 | 0.88 | KMT2A (0.98) | KMT2APDE5AALDH1A1CYP2D6GAA | |
| Hydrochloric Acid SCHEMBL6442412 | 0.88 | KMT2A (0.98) | KMT2APDE5AALDH1A1CYP2D6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1440709-B1 | Combinations comprising cGMP PDE5 inhibitors. | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20020040140-A1 | For therapy of male erectile dysfunction | PFIZER INC. | 2002-04-04 | — | — | US | disclosed |
| US-6350751-B1 | ANHYDROUS PARA-TOLUENESULPHONIC ACID SALTS OF 3-ETHYL-5-(5-(4-ETHYL PIPERAZIN-1-YLSULPHONYL)-2-(2-METHOXYETHOXY) PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)METHYL-2,6-DIHYDRO-7H-PYRAZOLO | PFIZER INC. | 2002-02-26 | — | — | US | disclosed |
| US-20020013464-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| US-20020013465-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001098303-A1 | NOVEL PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2001027101-A2 | ANHYDROUS SALT | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-1092720-A2 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | KMT2A 4533/4885PDE5A 1/4885ALDH1A1 254/4885 |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | KMT2A 4553/4885PDE5A 1/4885ALDH1A1 758/4885 |
| US-20020013465-A1 | Novel process for the preparation of pyrazolopyrimidinones | SDHA, NDUFS3, NDUFS2 | KMT2A 3944/4885PDE5A 1679/4885ALDH1A1 163/4885 |
| US-20020013464-A1 | Novel process for the preparation of pyrazolopyrimidinones | CYP4F3, CYP3A4, NDUFS3 | KMT2A 3952/4885PDE5A 895/4885ALDH1A1 812/4885 |
| US-20020040140-A1 | For therapy of male erectile dysfunction | PDE3A, PDE5A, PDE3B | KMT2A 4100/4885PDE5A 2/4885ALDH1A1 1787/4885 |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | KMT2A 3472/4885PDE5A 4/4885ALDH1A1 848/4885 |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | KMT2A 3472/4885PDE5A 4/4885ALDH1A1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.